Development of purine-scaffold small molecule inhibitors of Hsp90 Journal Article


Authors: Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N.
Article Title: Development of purine-scaffold small molecule inhibitors of Hsp90
Abstract: The Hsp90 chaperones play a key role in regulating the physiology of cells exposed to environmental stress and in maintaining the malignant phenotype in tumor cells. Agents that interfere with the function of the chaperone may thus be beneficial in the treatment of cancers. The ansamycins (geldanamycin and herbimycin) and the unrelated natural product radicicol were found to bind to the N-terminal pocket of Hsp90 and inhibit its function. However, translation of these compounds to the clinic was impeded by stability and hepatoxicity issues. 17AAG, a derivative of geldanamycin, was found to be less hepatotoxic and is currently undergoing Phase 1 clinical trial. Unfortunately, 17AAG is insoluble, difficult to formulate and it is not yet clear if therapeutically effective doses can be administered without escalating non-Hsp90 associated toxicities. Additionally, for reasons not yet completely understood, a subset of tumor cells are insensitive to the action of the drug. The development of novel agents that lack the drawbacks of the natural products is thus necessary. Here we present an overview of such efforts with focus on a new class of purine-scaffold Hsp90 inhibitors developed by rational design.
Keywords: unclassified drug; clinical trial; review; drug efficacy; nonhuman; antineoplastic agent; neoplasm; phenotype; animals; cell function; drug inhibition; drug design; drug synthesis; cancer cell; heat shock protein 90 inhibitor; hsp90 heat-shock proteins; stress; models, molecular; purines; purine derivative; ic 50; drug sensitivity; drug protein binding; protein inhibitor; drug formulation; geldanamycin; radicicol; drug solubility; 17 allylamino 17 demethoxygeldanamycin; humans; human
Journal Title: Current Cancer Drug Targets
Volume: 3
Issue: 5
ISSN: 1568-0096
Publisher: Bentham Science Publishers  
Date Published: 2003-10-01
Start Page: 371
End Page: 376
Language: English
DOI: 10.2174/1568009033481778
PUBMED: 14529388
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 25 September 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrea D. Basso
    32 Basso
  2. Neal Rosen
    425 Rosen
  3. David Solit
    779 Solit
  4. Gabriela Chiosis
    279 Chiosis
  5. Henri   Huezo
    11 Huezo
  6. Brian   Lucas
    9 Lucas
Related MSK Work